The following companies are expected to report earnings prior to market open on 09/23/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
InMed Pharmaceuticals Inc. (INM)is reporting for the quarter ending June 30, 2022. The drug company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-5.50. This value represents a 46.34% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for INM is -0.28 vs. an industry ratio of -0.80, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
